FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
暂无分享,去创建一个
Hong-wei Shen | Shanyang He | Yun-he Zhao | Wei Wang | Z. You | Zhiyong Wan | Jun Liu | Liwen Zhu
[1] Q. Jiang,et al. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] A. Warth,et al. FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC , 2019, Cancers.
[3] Weiqun Peng,et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer , 2018, Oncogene.
[4] M. Xie,et al. Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression , 2018, Cell Death & Disease.
[5] F. Pentimalli. BCL2: a 30-year tale of life, death and much more to come , 2017, Cell Death and Differentiation.
[6] W. Liu,et al. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation , 2017, Journal of Cancer.
[7] A. Weaver,et al. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. , 2017, Gynecologic oncology.
[8] Hongwei Jin,et al. Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding , 2017, Oncotarget.
[9] Shinya Watanabe,et al. FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma , 2015, International journal of oncology.
[10] Rocky Cipriano,et al. Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer , 2014, Molecular Cancer Research.
[11] M. Jackson,et al. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies , 2013, Oncotarget.
[12] Sarah A. Scott,et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. , 2012, The Journal of clinical investigation.
[13] C. Niehrs,et al. Mitotic and mitogenic Wnt signalling , 2012, The EMBO journal.
[14] Konrad Basler,et al. The many faces and functions of β‐catenin , 2012, The EMBO journal.
[15] Hans Clevers,et al. Wnt/β-Catenin Signaling and Disease , 2012, Cell.
[16] D. Oh,et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. , 2010, Cancer cell.
[17] Maya Breitman,et al. The armadillo repeat domain of the APC tumor suppressor protein interacts with Striatin family members. , 2008, Biochimica et biophysica acta.
[18] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[19] K. Kinzler,et al. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. , 2000, Cancer research.
[20] M. Klink,et al. Adenosine analogues as opposite modulators of the cisplatin resistance of ovarian cancer cells. , 2019, Anti-cancer agents in medicinal chemistry.
[21] Yoshinori Takahashi,et al. Analysis of Protein-Protein Interaction by Co-IP in Human Cells. , 2018, Methods in molecular biology.
[22] W. Weis,et al. The β-catenin destruction complex. , 2013, Cold Spring Harbor perspectives in biology.
[23] M. Leid,et al. Detection of apoptosis by TUNEL assay. , 2012, Methods in molecular biology.
[24] Celia Quevedo,et al. Biochemical mechanisms of cisplatin cytotoxicity. , 2007, Anti-cancer agents in medicinal chemistry.
[25] J. Lawry. Detection of apoptosis by the TUNEL assay. , 2004, Methods in molecular medicine.